Bioenvision to Present at UBS Global Life Sciences Conference
September 22 2006 - 6:07PM
Business Wire
Bioenvision, Inc. (NasdaqGM:BIVN) announced today that Dr.
Christopher B. Wood, Chairman and Chief Executive Officer, is
scheduled to present at the UBS Global Life Sciences Conference on
Monday, September 25, 2006 at 3:30pm (ET) at the Grand Hyatt, New
York City. A live webcast of the audio portion of this presentation
will be available via
http://events.streamx.us/US/event/EventDetails.aspx?id=ubs20060925
and will be archived and available for replay until October 28,
2006. About Bioenvision Bioenvision's primary focus is the
acquisition, development, distribution and marketing of compounds
and technologies for the treatment of cancer. Bioenvision has a
broad pipeline of products for the treatment of cancer, including:
Evoltra(R), Modrenal(R) (for which Bioenvision has obtained
regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products. Bioenvision is also
developing anti-infective technologies, including the OLIGON(R)
technology, an advanced biomaterial that has been incorporated into
various FDA approved medical devices and Suvus(TM), an
antimicrobial agent currently in clinical development for
refractory chronic hepatitis C infection. For more information on
Bioenvision please visit our Web site at www.bioenvision.com:
http://www.bioenvision.com. Certain statements contained herein are
"forward-looking" statements (as such term is defined in the
Private Securities Litigation Reform Act of 1995). Because these
statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied
by such forward-looking statements include, but are not limited to:
risks associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's
compounds under development in particular; the potential failure of
Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure
to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers,
licenses or strategic initiatives that change Bioenvision's
business, structure or projections; the development of competing
products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in
Bioenvision's filings with the SEC. Bioenvision disclaims any
obligation to update these forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From May 2024 to Jun 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2023 to Jun 2024